Brief: Mangoceuticals’ MGX-0024 Achieves Zero Respiratory-Related Mortality, Shows H5n1 Prophylactic Benefit

Mangoceuticals

23/02/2026 21:47

Feb 23 (Reuters) - Mangoceuticals Inc MGRX.O:

MANGOCEUTICALS’ PATENTED MGX-0024 ACHIEVES ZERO RESPIRATORY-RELATED MORTALITY IN 29,000-BIRD FIELD TRIALS AND DEMONSTRATES PROPHYLACTIC BENEFIT AGAINST H5N1 IN CONTROLLED GOVERNMENT STUDY

MANGOCEUTICALS INC - MORTALITY REDUCED BY UP TO 60% IN PRE-TREATMENT GROUP

Source text: ID:nGNX1MW6bZ

Further company coverage: MGRX.O

 ((Reuters.Briefs@thomsonreuters.com;))